Quick Asked: Electrocore Contact Us?
Last update: 12 Apr, 2024 
138 Views
What is the patent number for electrocore? ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methodsWhats new at electrocore? ROCKAWAY, NJ , Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC . (Red One). The partnership will further expand availability of electroCore’s gammaCoreWho is the chief medical officer of electrocore? As electroCore’s Chief Medical Officer, Dr. Peter Staats is responsible for overseeing the ongoing clinical development of gammaCore™ and works to advance the technology into new potential indications. Dr. Staats is a co-founder of electroCore and has previously served on the board of directors.When will electrocore report q2 earnings? ROCKAWAY, NJ , July 22, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021 .
Listing Results Electrocore Contact Us? Question Answers
Investor Relations electroCore
ROCKAWAY, NJ , Dec. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients residing in the United Kingdom .
ElectroCore Overview, News & Competitors ...
GammaCore (nVNS): NonDrug Relief for Migraine & ...
gammaCore TM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore is indicated for:. The preventive treatment of migraine headache in adolescent (age 12 and older) and adult patients. The acute treatment of pain associated with migraine headache in adolescent (age 12 and older) and ...
Our Leadership electroCore
The leadership team brings a broad set of talents and skills across the medical device and pharmaceutical industries and has a shared vision that innovation will advance the treatment of difficult-to-treat conditions in neurology and rheumatology. Daniel S. Goldberger. Chief Executive Officer. Peter S. Staats, MD, MBA.